Motif Bio PLC PRESENTING THREE POSTERS ON ICLAPRIM AT ID WEEK

TIDMMTFB

Motif Bio PLC

06 July 2017

6 July 2017

Motif Bio plc

("Motif" or the "Company")

MOTIF BIO TO PRESENT THREE POSTERS AT ID WEEK 2017

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that three abstracts have been accepted for poster presentations at the Infectious Diseases Week Annual Meeting in San Diego 4-8 October 2017.

The title and description of each poster and presentation times are noted below. All posters will be exhibited at the San Diego Convention Center Halls CD. The posters will be made available on the company's website following their presentation at the conference.

(1) A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens (REVIVE-1). This is a 600 patient study comparing iclaprim 80 mg to vancomycin 15 mg/kg both administered intravenously every 12 hours for 5 to 14 days at the endpoints: early clinical response (20% or more reduction in lesion size) and test of cure (resolution of signs and symptoms of ABSSSI such that no further antibiotics are needed). These data will be presented at the Clinical Study with New Antibiotics and Antifungals session on Saturday October 7, between 12.30 and 2.00pm (Abstract 63284).

(2) Effects of Iclaprim and Trimethoprim on Exotoxin Production by Methicillin-resistant Staphylococcus aureus. This is an in vitro study comparing the effects of sub-inhibitory doses of dihydrofolate reductase inhibitors with cell wall-active agents on transcription and translation of important and common toxins (alpha hemolysin, Panton-Valentine Leukocidin and toxic shock syndrome toxin-1) from two clinical MRSA isolates. These data will be presented at the Expanded Spectrum - New Antimicrobial Susceptibility Testing session on Friday October 6, between 12.30 and 2.00pm. (Abstract 64753).

(3) Efficacy Evaluation of Iclaprim in a Neutropenic Rat Lung Infection Model with Methicillin-Resistant Staphylococcus aureus Entrapped in Alginate Microspheres. This is an in vivo study comparing the colony forming unit (CFU) reduction and mortality of rats in an experimental animal model of a chronic pulmonary infection using a strain of methicillin resistant S. aureus and treatment with iclaprim compared to vancomycin. Bacterial reduction and mortality were measured in this experimental animal model of a chronic pulmonary infection which mimics the pathophysiology observed in patients with cystic fibrosis. These data will be presented at the Preclinical Study with New Antibiotics and Antifungals session on Friday October 6, between 12.30 and 2.00pm. (Abstract 63283).

 
 Motif Bio plc                                               [e-mail] 
  Graham Lumsden (Chief 
  Executive Officer) 
  David Huang (Chief Medical 
  Officer) 
 Walbrook PR Ltd. (FINANCIAL    [phone] or [e-mail] 
  PR & IR)                                            Mob: [phone] 
  Paul McManus                                        Mob: [phone] 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                            [phone] 
 

Notes to Editors

About iclaprim

Iclaprim is a novel antibiotic candidate, designed to be effective against bacteria that have developed resistance to other antibiotics. Iclaprim exhibits potent activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). The MIC(90) of iclaprim was lower, demonstrating higher potency, than most comparators including vancomycin and linezolid, standard of care therapies used in serious and life-threatening Gram-positive hospital infections. To date, iclaprim has been studied in over 1,000 patients and healthy volunteers. No dosage adjustment is required in patients with renal impairment, or in obese patients. The iclaprim fixed dose may help reduce the resources required in hospitals since dosage adjustment by health care professionals is avoided, and overall hospital treatment costs may be lower, especially in renally impaired patients

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin-resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.

IDWeek

Is a global conference attended by over 6000 healthcare professionals practicing or involved in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists. In addition, public health officials, including those who see HIV and pediatric patients attend in numbers. It is a meeting for professionals who want to stay current and apply state-of-the art science to clinical care, and excel in their own career.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRARAMFTMBMMBMR

(END) Dow Jones Newswires

July 06, 2017 02:00 ET (06:00 GMT)